Ceritinib Fails to Penetrate Tumors in Glioblastoma Trial
A study shows the drug struggles to reach necessary levels in the brain, impacting potential use for recurrent glioblastoma.
Updated on Oct. 16, 2026 in Cancer
A phase 0 clinical trial of the drug ceritinib for patients with recurrent glioblastoma has found the therapy failed to penetrate tumor tissue effectively. The study, published October 16, 2026, demonstrated that the medication did not reach necessary levels to engage its intended targets within the brain.
Why it matters
Glioblastoma remains difficult to treat in part because many drugs struggle to cross the blood-brain barrier. This finding highlights why researchers continue to face challenges in developing small-molecule therapies that can sufficiently reach and inhibit targets within intracranial tumors.
In a phase 0 clinical trial, researchers found that the median unbound fraction of ceritinib in tumor tissue was 0.051%, compared to 1.4% in plasma. The study evaluated tumor samples to measure target engagement, but found no significant changes in cellular proliferation or apoptosis.
The details
Ceritinib is designed to act as a small-molecule inhibitor of specific proteins, including ALK, IGF1R, and FAK. During the study, participants were given oral ceritinib before undergoing surgical resection so that tumor tissue could be analyzed. The researchers discovered that the drug's restricted penetration into intracranial lesions meant free concentrations remained below the biochemical levels required to effectively inhibit target proteins.
Timeline
October 16, 2026: The study results were officially published.
Health Landscape
Treating glioblastoma remains a significant hurdle in neuro-oncology due to the blood-brain barrier, which frequently prevents systemic drugs from reaching therapeutic levels in the brain. This trial adds to the body of evidence illustrating the limitations of standard small-molecule inhibitors in this setting.
This study highlights the biological difficulty of treating brain tumors and does not change current standard-of-care protocols for patients. Individuals managing a glioblastoma diagnosis should discuss all potential clinical trial options and emerging treatment strategies with their oncologist.
The takeaway
The primary takeaway is that achieving effective drug concentration within intracranial tumors is a major obstacle for many small-molecule inhibitors. Patients and their families are encouraged to maintain a regular dialogue with their medical team regarding the latest developments in neuro-oncology research.
Further reading
For more information on the current state of neuro-oncology, visit the Cancer section.
